223 related articles for article (PubMed ID: 37622400)
1. p53 amyloid pathology is correlated with higher cancer grade irrespective of the mutant or wild-type form.
Sengupta S; Singh N; Paul A; Datta D; Chatterjee D; Mukherjee S; Gadhe L; Devi J; Mahesh Y; Jolly MK; Maji SK
J Cell Sci; 2023 Sep; 136(17):. PubMed ID: 37622400
[TBL] [Abstract][Full Text] [Related]
2. p53 amyloid formation leading to its loss of function: implications in cancer pathogenesis.
Ghosh S; Salot S; Sengupta S; Navalkar A; Ghosh D; Jacob R; Das S; Kumar R; Jha NN; Sahay S; Mehra S; Mohite GM; Ghosh SK; Kombrabail M; Krishnamoorthy G; Chaudhari P; Maji SK
Cell Death Differ; 2017 Oct; 24(10):1784-1798. PubMed ID: 28644435
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic gain of function due to p53 amyloids occurs through aberrant alteration of cell cycle and proliferation.
Navalkar A; Paul A; Sakunthala A; Pandey S; Dey AK; Saha S; Sahoo S; Jolly MK; Maiti TK; Maji SK
J Cell Sci; 2022 Aug; 135(15):. PubMed ID: 35796018
[TBL] [Abstract][Full Text] [Related]
4. Relationship between p63 and p53 expression in Merkel cell carcinoma and corresponding abnormalities in TP63 and TP53: a study and a proposal.
DeCoste RC; Carter MD; Pasternak S; Fleming KE; Gaston D; Legge A; Ly TY; Walsh NM
Hum Pathol; 2021 Nov; 117():31-41. PubMed ID: 34391748
[TBL] [Abstract][Full Text] [Related]
5. Direct evidence of cellular transformation by prion-like p53 amyloid infection.
Navalkar A; Pandey S; Singh N; Patel K; Datta D; Mohanty B; Jadhav S; Chaudhari P; Maji SK
J Cell Sci; 2021 Jun; 134(11):. PubMed ID: 34085695
[TBL] [Abstract][Full Text] [Related]
6. TP53 family members and human cancers.
Bénard J; Douc-Rasy S; Ahomadegbe JC
Hum Mutat; 2003 Mar; 21(3):182-91. PubMed ID: 12619104
[TBL] [Abstract][Full Text] [Related]
7. Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors.
Levy CB; Stumbo AC; Ano Bom AP; Portari EA; Cordeiro Y; Silva JL; De Moura-Gallo CV
Int J Biochem Cell Biol; 2011 Jan; 43(1):60-4. PubMed ID: 21056685
[TBL] [Abstract][Full Text] [Related]
8. Amyloidogenicity of p53: a hidden link between protein misfolding and cancer.
Gong H; Yang X; Zhao Y; Petersen RB; Liu X; Liu Y; Huang K
Curr Protein Pept Sci; 2015; 16(2):135-46. PubMed ID: 25692950
[TBL] [Abstract][Full Text] [Related]
9. TP63 mutations are frequent in cutaneous melanoma, support UV etiology, but their role in melanomagenesis is unclear.
Monti P; Ghiorzo P; Menichini P; Foggetti G; Queirolo P; Izzotti A; Fronza G
Oncol Rep; 2017 Oct; 38(4):1985-1994. PubMed ID: 28849221
[TBL] [Abstract][Full Text] [Related]
10. IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo.
Venkatanarayan A; Raulji P; Norton W; Chakravarti D; Coarfa C; Su X; Sandur SK; Ramirez MS; Lee J; Kingsley CV; Sananikone EF; Rajapakshe K; Naff K; Parker-Thornburg J; Bankson JA; Tsai KY; Gunaratne PH; Flores ER
Nature; 2015 Jan; 517(7536):626-30. PubMed ID: 25409149
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer.
Silva JL; Cino EA; Soares IN; Ferreira VF; A P de Oliveira G
Acc Chem Res; 2018 Jan; 51(1):181-190. PubMed ID: 29260852
[TBL] [Abstract][Full Text] [Related]
12. The aggregation of mutant p53 produces prion-like properties in cancer.
Rangel LP; Costa DC; Vieira TC; Silva JL
Prion; 2014; 8(1):75-84. PubMed ID: 24509441
[TBL] [Abstract][Full Text] [Related]
13. Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer.
Ano Bom AP; Rangel LP; Costa DC; de Oliveira GA; Sanches D; Braga CA; Gava LM; Ramos CH; Cepeda AO; Stumbo AC; De Moura Gallo CV; Cordeiro Y; Silva JL
J Biol Chem; 2012 Aug; 287(33):28152-62. PubMed ID: 22715097
[TBL] [Abstract][Full Text] [Related]
14. Methods to Screen Compounds Against Mutant p53 Misfolding and Aggregation for Cancer Therapeutics.
Ferretti GDDS; da Costa DCF; L Silva J; Pereira Rangel L
Methods Mol Biol; 2019; 1873():265-277. PubMed ID: 30341616
[TBL] [Abstract][Full Text] [Related]
15. Expression of the p53 homologues p63 and p73 in multiple simultaneous gastric cancer.
Tannapfel A; Schmelzer S; Benicke M; Klimpfinger M; Kohlhaw K; Mössner J; Engeland K; Wittekind C
J Pathol; 2001 Sep; 195(2):163-70. PubMed ID: 11592094
[TBL] [Abstract][Full Text] [Related]
16. TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73.
Liu K; Ling S; Lin WC
Mol Cell Biol; 2011 Nov; 31(22):4464-81. PubMed ID: 21930790
[TBL] [Abstract][Full Text] [Related]
17. Prion-like p53 Amyloids in Cancer.
Navalkar A; Ghosh S; Pandey S; Paul A; Datta D; Maji SK
Biochemistry; 2020 Jan; 59(2):146-155. PubMed ID: 31603660
[TBL] [Abstract][Full Text] [Related]
18. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo.
Concin N; Becker K; Slade N; Erster S; Mueller-Holzner E; Ulmer H; Daxenbichler G; Zeimet A; Zeillinger R; Marth C; Moll UM
Cancer Res; 2004 Apr; 64(7):2449-60. PubMed ID: 15059898
[TBL] [Abstract][Full Text] [Related]
19. Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor.
Silva JL; Rangel LP; Costa DC; Cordeiro Y; De Moura Gallo CV
Biosci Rep; 2013 Jul; 33(4):. PubMed ID: 24003888
[TBL] [Abstract][Full Text] [Related]
20. Loss of the p53 transactivation domain results in high amyloid aggregation of the Δ40p53 isoform in endometrial carcinoma cells.
Melo Dos Santos N; de Oliveira GAP; Ramos Rocha M; Pedrote MM; Diniz da Silva Ferretti G; Pereira Rangel L; Morgado-Diaz JA; Silva JL; Rodrigues Pereira Gimba E
J Biol Chem; 2019 Jun; 294(24):9430-9439. PubMed ID: 31028175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
